Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia

Translated title of the contribution: Cardiovascular calcification and atherosclerosis accelerated during uremia

Mario Cozzolino, Alessandra Butti, Giusy Chiarelli, Lisa Rocca-Rey, Gaia Santagostino, Maurizio Gallieni, Diego Brancaccio

Research output: Contribution to journalArticlepeer-review


Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.

Translated title of the contributionCardiovascular calcification and atherosclerosis accelerated during uremia
Original languageItalian
Pages (from-to)25-28
Number of pages4
JournalItalian Heart Journal Supplement
Issue number1
Publication statusPublished - Jan 2005

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular calcification and atherosclerosis accelerated during uremia'. Together they form a unique fingerprint.

Cite this